Stock BTAX BIOSTAX CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Biostax Corp.

Equities

BTAX

US45252A3059

Delayed OTC Markets
Other stock markets
 09:03:59 03/06/2024 pm IST 		5-day change 1st Jan Change
0.0425 USD +21.40% Intraday chart for Biostax Corp. +18.06% -41.78%
20/05 Biostax Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
16/04 Biostax Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception
AQ
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro
AQ
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors
AQ
Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment
AQ
Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky
AQ
Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV
AQ
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH
AQ
Biostax Launches Growth Funding Round to Revitalize Affordable Healthcare
PR
Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies
AQ
IMMUNE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
IMMUNE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)
AQ
IMMUNE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction
AQ
IMMUNE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
IMMUNE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q)
AQ
IMMUNE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development
AQ
IMMUNE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors
AQ
IMMUNE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BTAX Stock
  4. News Biostax Corp.
  5. Press Releases